The payment represents the final phase of the Plavix patent litigation between the companies and Apotex, which was initiated in 21March 2002.
Apotex also paid $1,258,682 in interest on the judgement given by US Court of Appeals for the Federal Circuit in October 2011 and another $900,000 in costs in addition to the damages award.
Sanofi and Bristol said they are pleased that Apotex has made reparation of the harm caused by the launch of a generic clopidogrel bisulfate in 2006.